Effect of acid suppressants on the efficacy of tyrosine kinase inhibitors in patients with epidermal growth factor receptor‑mutated non‑small‑cell lung cancer

Miyazaki,Kunihiko; Sato,Shinya; Kodama,Takahide; Tamura,Tomohiro; Kagohashi,Katsunori; Satoh,Hiroaki; Hizawa,Nobuyuki

doi:10.3892/mco.2016.810

May-2016 Volume 4 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

May-2016 Volume 4 Issue 5

Full Size Image

Article

Effect of acid suppressants on the efficacy of tyrosine kinase inhibitors in patients with epidermal growth factor receptor‑mutated non‑small‑cell lung cancer

Authors:
- Kunihiko Miyazaki
- Shinya Sato
- Takahide Kodama
- Tomohiro Tamura
- Katsunori Kagohashi
- Hiroaki Satoh
- Nobuyuki Hizawa
View Affiliations / Copyright

Affiliations: Ryugasaki Saiseikai General Hospital, Ryugasaki, Ibaraki 135‑0033, Japan, Faculty of Medicine, Institute of Clinical Medicine, University of Tsukuba, Tsukuba 305‑8575, Japan, Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba Hospital, University of Tsukuba, Mito, Ibaraki 310‑0015, Japan
Pages: 873-877
|
Published online on: March 9, 2016

https://doi.org/10.3892/mco.2016.810
Expand metrics +

Abstract

This retrospective study was conducted to evaluate whether oral acid suppressant (AS) therapy is associated with decreased efficacy of gefitinib and erlotinib, particularly in patients with mutated epidermal growth factor receptor (EGFR). A total of 46 consecutive patients with pathologically confirmed non‑small‑cell lung cancer (NSCLC), who were treated with tyrosine kinase inhibitors (TKIs) in two tertiary hospitals between September, 2005 and May, 2013, were retrospectively analyzed. of the 46 patients, 11 received AS treatment. As regards age, gender, smoking history, performance status, histology of lung cancer, clinical stage, body surface area (BSA) and type of EGFR mutation, there were no statistically significant differences between patients with and those without AS treatment. There was no statistically significant difference in progression‑free survival (PFS) or overall survival (OS) between the two groups of patients (P=0.296 and 0.613, respectively). As regards the relative dose of TKI̸BSA and survival in patients with and those without AS treatment, there were no statistically significant differences in PFS and OS between the two groups of patients. Our study indicates that AS treatment may not compromise TKI efficacy (gefitinib or erlotinib) in NSCLC patients with mutated EGFR. Prospective studies and large‑scale confirmation studies investigating the effect of AS co‑administration with TKIs in patients with mutated EGFR may be meaningful in clinical practice.

View Figures

View References

1	Achem SR and DeVault KR: Gastroesophageal reflux disease and the elderly. Gastroenterol Clin North Am. 43:147–160. 2014. View Article : Google Scholar : PubMed/NCBI
2	Keynes WM: Medical response to mental stress. J R Soc Med. 87:536–539. 1994.PubMed/NCBI
3	US Food and Drug Administration: Center for Drug Evaluation and Research. Tarceva NDA 21–743/S000 clinical pharmacology and biopharmaceutics review. November 18–2004.http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-743_Tarceva_biopharmr.PDFAccessed. May 01–2014
4	Budha NR, Frymoyer A, Smelick GS, Jin JY, Yago MR, Dresser MJ, Holden SN, Benet LZ and Ware JA: Drug absorption interactions between oral targeted anticancer agents and PPIs: Is pH-dependent solubility the Achilles heel of targeted therapy? Clin Pharmacol Ther. 92:203–213. 2012. View Article : Google Scholar : PubMed/NCBI
5	Chu MP, Ghosh S, Chambers CR, Basappa N, Butts CA, Chu Q, Fenton D, Joy AA, Sangha R, Smylie M and Sawyer MB: Gastric acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer. Clin Lung Cancer. 16:33–39. 2015. View Article : Google Scholar : PubMed/NCBI
6	Hilton JF, Tu D, Seymour L, Shepherd FA and Bradbury PA: An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib. Lung Cancer. 82:136–142. 2013. View Article : Google Scholar : PubMed/NCBI
7	Ter Heine R, Fanggiday JC, Lankheet NA, Beijnen JH, Van Der Westerlaken MM, Staaks GH and Malingré MM: Erlotinib and pantoprazole: A relevant interaction or not? Br J Clin Pharmacol. 70:908–911. 2010. View Article : Google Scholar : PubMed/NCBI
8	Travis WD, Brambilla E, Muller-Hermelink HK and Harris CC: Pathology and genetics: Tumours of the Lung, Pleura, Thymus and Heart. IARC Press. Lyon: 9–122. 2004.
9	Vallières E, Shepherd FA, Crowley J, et al: International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions: The IASLC Lung Cancer Staging Project: Proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 4:1049–1059. 2009. View Article : Google Scholar : PubMed/NCBI
10	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
11	Costa DB, Nguyen KS, Cho BC, Sequist LV, Jackman DM, Riely GJ, Yeap BY, Halmos B, Kim JH, Jänne PA, et al: Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res. 14:7060–7077. 2008. View Article : Google Scholar : PubMed/NCBI
12	Rukazenkov Y, Speake G, Marshall G, Anderton J, Davies BR, Wilkinson RW, Hickinson Mark D and Swaisland A: Epidermal growth factor receptor tyrosine kinase inhibitors: Similar but different? Anticancer Drugs. 20:856–866. 2009. View Article : Google Scholar : PubMed/NCBI
13	O'Malley M, King AN, Conte M, Ellingrod VL and Ramnath N: Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer. J Thorac Oncol. 9:917–926. 2014. View Article : Google Scholar : PubMed/NCBI
14	Yeo WL, Riely GJ, Yeap BY, Lau MW, Warner JL, Bodio K, Huberman MS, Kris MG, Tenen DG, Pao W, et al: Erlotinib at a dose of 25 mg daily for non-small-cell lung cancers with EGFR mutations. J Thorac Oncol. 5:1048–1053. 2010. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Effect of acid suppressants on the efficacy of tyrosine kinase inhibitors in patients with epidermal growth factor receptor‑mutated non‑small‑cell lung cancer

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles